RT Journal Article
T1 Quantitative Analysis of Somatostatin and Dopamine Receptors Gene Expression Levels in Non-functioning Pituitary Tumors and Association with Clinical and Molecular Aggressiveness Features
A1 Flores-Martinez, Álvaro
A1 Venegas-Moreno, Eva
A1 Dios, Elena
A1 Remón-Ruiz, Pablo
A1 Gros-Herguido, Noelia
A1 Vázquez-Borrego, M. Carmen
A1 Madrazo-Atutxa, Ainara
A1 Japón, Miguel A.
A1 Kaen, Ariel
A1 Cárdenas-Valdepeñas, Eugenio
A1 Roldán, Florinda
A1 Castaño, Justo P.
A1 Luque, Raúl M.
A1 Cano, David A.
A1 Soto-Moreno, Alfonso
K1 Pituitary tumor
K1 Invasion
K1 Somatostatin receptor
K1 Dopamine receptor
K1 Non-functioning pituitary tumors
K1 Dopamine agonists
K1 Neoplasias hipofisarias
K1 Receptores de somatostatina
K1 Receptores dopaminérgicos
K1 Agonistas de dopamina
K1 Andalucía
AB The primary treatment for non-functioning pituitary tumors (NFPTs) is surgery, but it is often unsuccessful. Previous studies have reported that NFPTs express receptors for somatostatin (SST1-5) and dopamine (DRDs) providing a rationale for the use of dopamine agonists and somatostatin analogues. Here, we systematically assessed SST1-5 and DRDs expression by real-time quantitative PCR (RT-qPCR) in a large group of patients with NFPTs (n = 113) and analyzed their potential association with clinical and molecular aggressiveness features. SST1-5 expression was also evaluated by immunohistochemistry. SST3 was the predominant SST subtype detected, followed by SST2, SST5, and SST1. DRD2 was the dominant DRD subtype, followed by DRD4, DRD5, and DRD1. A substantial proportion of NFPTs displayed marked expression of SST2 and SST5. No major association between SSTs and DRDs expression and clinical and molecular aggressiveness features was observed in NFPTs.
PB MDPI
YR 2020
FD 2020-09-22
LK http://hdl.handle.net/10668/4545
UL http://hdl.handle.net/10668/4545
LA en
NO Flores-Martinez Á, Venegas-Moreno E, Dios E, Remón-Ruiz P, Gros-Herguido N, Vázquez-Borrego MC, et al. Quantitative Analysis of Somatostatin and Dopamine Receptors Gene Expression Levels in Non-functioning Pituitary Tumors and Association with Clinical and Molecular Aggressiveness Features. J Clin Med. 2020 Sep 22;9(9):3052
DS RISalud
RD Apr 7, 2025